SBC Medical Group (NASDAQ:SBC) Shares Gap Down - Should You Sell?

Key Points

• SBC Medical Group shares opened lower, falling from a prior close of $5.37 to $5.19 before recovering to about $5.35.
• Analyst sentiment remains favorable: the stock has a “Moderate Buy” consensus rating and an average price target of $8.50, with targets including BTIG Research’s $8.00.
• The company beat revenue expectations but missed quarterly earnings estimates, reporting $0.10 EPS versus the $0.12 consensus on revenue of $49.19 million. Institutional investors own approximately 60.82% of the shares.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Get Free Report)'s stock price gapped down before the market opened on Wednesday. The stock had previously closed at $5.37, but opened at $5.19. SBC Medical Group shares last traded at $5.3450, with a volume of 21,291 shares trading hands.

Analysts Set New Price Targets

A number of research analysts recently issued reports on SBC shares. BTIG Research restated a "buy" rating and set a $8.00 target price on shares of SBC Medical Group in a research report on Thursday, August 13th. Weiss Ratings upgraded SBC Medical Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, October 9th. Finally, Wall Street Zen raised SBC Medical Group from a "buy" rating to a "strong-buy" rating in a report on Monday, October 5th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.50.

SBC Medical Group Stock Performance

The firm's 50 day moving average price is $4.76 and its two-hundred day moving average price is $3.91. The firm has a market cap of $551.77 million, a PE ratio of 11.38 and a beta of 0.56.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.02). The firm had revenue of $49.19 million during the quarter, compared to analyst estimates of $45.37 million. On average, analysts forecast that SBC Medical Group Holdings Incorporated will post 0.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SBC. BlackRock Inc. acquired a new stake in SBC Medical Group during the 2nd quarter worth approximately $2,846,000. Citadel Advisors LLC purchased a new stake in shares of SBC Medical Group during the second quarter worth $446,000. Segall Bryant & Hamill LLC purchased a new stake in shares of SBC Medical Group during the first quarter worth $340,000. State Street Corp increased its position in shares of SBC Medical Group by 59.7% during the second quarter. State Street Corp now owns 49,239 shares of the company's stock worth $152,000 after acquiring an additional 18,400 shares during the period. Finally, Williams & Novak Wealth Management LLC raised its stake in shares of SBC Medical Group by 40.9% in the third quarter. Williams & Novak Wealth Management LLC now owns 26,330 shares of the company's stock valued at $130,000 after acquiring an additional 7,644 shares in the last quarter. Institutional investors and hedge funds own 60.82% of the company's stock.

SBC Medical Group Company Profile

SBC Medical Group Holdings Incorporated is a Japan-based healthcare services company focused on supporting aesthetic medicine and related medical institutions. Through its group companies, the business provides operational and management support designed to help clinics deliver cosmetic surgery, dermatology, and other elective medical services.

The company's services include clinic management consulting, marketing, staff recruitment and training, procurement, information technology, and administrative support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.